Overview
Keyin Biology develops innovative AI drugs. It rapidly built a first-principles de novo drug design platform that systematically explores chemical space and improves virtual discovery for new targets. By efficiently integrating upstream and downstream partners and coordinating internal and external R&D, it improves the DMTA cycle and reduces experimentation costs and timelines.
Connected profiles
Explore
More Health management products
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
科因生物是一家AI创新药物研发商，科因生物成立以来，迅速搭建了基于第一性原理的从头药物设计平台，可以对全化学空间进行系统性探索，增强了针对新靶点的虚拟发现能力。团队通过高效整合上下游合作伙伴，充分发挥内外研发协同效应，极大提升了DMTA循环效率，降低了试错成本和周期。